Long-lasting cross-presentation of tumor antigen in human DC

European Journal of Immunology
Florence FaureS Amigorena

Abstract

DC cross-present exogenous antigens on MHC class I molecules, a process required for the onset of anti-tumor immune responses. In order to study the cross-presentation of tumor antigens by human DC, we compared the pathways of cross-presentation of long peptides requiring internalization and intracellular processing with the direct presentation of short peptides, which does not require intracellular processing. We found that, after brief incubations with DC, short peptides were presented to CD8(+) T cells with higher efficiencies than long peptides. After longer times of chase in the absence of peptide, however, the efficiency of presentation of the two types of peptides was reversed. After 2-3 days, DC pulsed with long peptides still activated T cells efficiently, while DC pulsed with short peptides failed to do so. Long-lasting presentation of the long peptides was, at least in part, due to a stored persistent pool of antigen, which was still available for loading on MHC class I molecules after several days of chase. These results show that the use of long synthetic peptides allows the efficient, long-lasting, presentation of tumor antigens, suggesting that long peptides represent an interesting approach for active anti-tumor...Continue Reading

References

Jun 12, 1998·Nature·A Lanzavecchia
Dec 22, 1998·The Journal of Experimental Medicine·K HungH Levitsky
Mar 15, 2001·Traffic·M J KleijmeerH J Geuze
Apr 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J L PooleyK Shortman
Jul 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·I MottaP Kourilsky
Jun 22, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sander ZwavelingCornelis J M Melief
Jul 26, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yasuhiro NagataIra Mellman
Aug 3, 2002·Nature Reviews. Immunology·Clotilde ThérySebastian Amigorena
Apr 12, 2003·Science·Joseph C Sun, Michael J Bevan
Jun 12, 2003·Journal of Immunological Methods·Peter ThumannLars Jenne
Oct 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Anne L AckermanPeter Cresswell
Oct 29, 2003·Journal of Immunological Methods·Michael R BettsRichard A Koup
Apr 23, 2004·Trends in Immunology·Gabriel MorónClaude Leclerc
May 11, 2004·Cancer Immunology, Immunotherapy : CII·Dirk NagorsenFrédéric Lévy
May 22, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Robin M CiscoScott K Pruitt
Sep 2, 2004·Nature Medicine·Steven A RosenbergNicholas P Restifo
Nov 4, 2004·The Lancet Oncology·Simone MocellinDonato Nitti
Nov 6, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Laurence ChapatteFrédéric Lévy
Dec 14, 2004·Springer Seminars in Immunopathology·Pierre Guermonprez, Sebastian Amigorena
Feb 3, 2005·European Journal of Immunology·Sandro PratoJosé Alejandro López
Feb 8, 2005·The Journal of Clinical Investigation·Daniel E SpeiserPedro Romero
Mar 18, 2005·Annual Review of Immunology·Jonathan W Yewdell, S M Mansour Haeryfar
Sep 15, 2005·The Journal of Experimental Medicine·Daniele AccapezzatoVincenzo Barnaba
Jan 6, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jacques ChapiroBenoît J Van den Eynde
Mar 23, 2006·Annual Review of Immunology·Thierry BoonPierre van der Bruggen
May 13, 2006·Nature Reviews. Immunology·Caetano Reis e Sousa
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gilles BioleyPedro Romero

❮ Previous
Next ❯

Citations

Apr 2, 2013·Trends in Immunology·Stefan NierkensGosse J Adema
Oct 10, 2012·Proceedings of the National Academy of Sciences of the United States of America·Changying LiPramod K Srivastava
May 19, 2010·The Journal of Experimental Medicine·Lionel Franz PoulinCaetano Reis e Sousa
Sep 23, 2009·Current Opinion in Oncology·Khashayarsha KhazaiePhilipp Beckhove
Sep 29, 2011·The Cancer Journal·Gerold Schuler
Oct 6, 2010·Journal of Translational Medicine·Maja BürdekChristiane Geiger
Oct 12, 2010·Clinical & Developmental Immunology·Joel F AldrichRonald C Kennedy
Oct 26, 2011·Nanomedicine : Nanotechnology, Biology, and Medicine·Seyed Amir JalaliMahmoud Reza Jaafari
May 8, 2010·Current Opinion in Immunology·Jonathan W Yewdell
Jul 18, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna SchurichPercy Knolle
Jan 13, 2015·Current Opinion in Immunology·Justine D MinternJose A Villadangos
May 2, 2014·Frontiers in Immunology·Cynthia M FehresYvette van Kooyk
Aug 16, 2016·Experimental Cell Research·Piyushi GuptaEllora Sen
Sep 17, 2016·PLoS Pathogens·Karsten EichholzEric J Kremer
Mar 16, 2017·Expert Review of Vaccines·Sandra ScheiblhoferJosef Thalhamer
Sep 9, 2017·International Journal of Cancer. Journal International Du Cancer·Florence FaureSebastian Amigorena
Jul 14, 2012·Nature Reviews. Immunology·Olivier P JoffreSebastian Amigorena
Sep 21, 2010·European Journal of Immunology·Gerold Schuler
Sep 22, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lothar HambachEls Goulmy
Aug 7, 2020·The FEBS Journal·Roni Levin-Konigsberg, Adriana R Mantegazza
Jan 23, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Wenbin MaBenoît J Van den Eynde
Feb 1, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Joë-Marc ChauvinFrancine Jotereau
Oct 28, 2019·Bioscience Reports·Vaishnavi U WarrierRajesh Kumar Gupta
Jul 14, 2020·The Journal of Experimental Medicine·Jonathan J HubbardRichard S Blumberg
Jan 30, 2021·Targeted Oncology·Michael A MorseDuane A Mitchell
Apr 4, 2021·Vaccines·Sasheen DowlathVernon K Ward
Dec 24, 2017·Molecular Immunology·Ralph E Vatner, Edith M Janssen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.